French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy (ESGT)

Journal of Gene Medicine

Volumn 5, Issue 1, 2003, Pages 82-84

  Gänsbacher, Bernd ^a   Danos, Olivier ^a   Dickson, George ^a   Thielemans, Kris ^a   Cosset, François Loic ^a   Deglon, Nicole ^a   Dilber, M Sirac ^a   Galun, Eithan ^a   Klatzmann, David ^a   Mavilio, Fulvio ^a   Taylor, Naomi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2 RECEPTOR; RETROVIRUS VECTOR;

ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CHICKENPOX; CHROMOSOME 11; COMBINED IMMUNODEFICIENCY; FAMILY HISTORY; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEALTH CARE ACCESS; HUMAN; INFORMED CONSENT; LEUKEMOID REACTION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; MEDICAL ETHICS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; X CHROMOSOME LINKED DISORDER; CLINICAL TRIAL; EUROPE; GENE THERAPY; GENETICS; LEGAL ASPECT; PROFESSIONAL STANDARD;

CLINICAL TRIALS; CLINICAL TRIALS DATA MONITORING COMMITTEES; EUROPE; GENE THERAPY; GENETIC DISEASES, X-LINKED; HUMANS; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 0037590036     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.364     Document Type: Article

References (0)